Literature DB >> 27489336

Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects.

Roy Eldor1, Giuseppe Daniele1, Claudia Huerta2, Mariam Al-Atrash1, John Adams1, Ralph DeFronzo1, Timothy Duong2, John Lancaster2, Mahmoud Zirie3, Amin Jayyousi3, Muhammad Abdul-Ghani4.   

Abstract

OBJECTIVE: This study examined the effect of exenatide on brain activity measured by functional (f)MRI and on insulin secretion in lean and obese normal-glucose-tolerant individuals. RESEARCH DESIGN AND METHODS: The brain fMRI signal in response to high-calorie-content food pictures was measured with and without intravenous exenatide infusion in 10 lean and 10 obese healthy volunteers. Insulin secretion was measured with a two-step (+100 and +200 mg/dL) hyperglycemic clamp with exenatide and with saline infusion.
RESULTS: The brain fMRI signal in response to food pictures in amygdala, insula, hippocampus, and frontal cortex was significantly greater in obese versus lean individuals. Intravenous exenatide significantly inhibited the fMRI signal in response to food pictures in obese individuals but did not affect the brain fMRI signal in lean subjects. Conversely, exenatide infusion caused an 18.5-fold increase in insulin secretion in lean individuals compared with an 8.8-fold increase in obese subjects. No significant correlation was observed between inhibition of the brain fMRI signal and increase in insulin secretion during exenatide infusion.
CONCLUSIONS: Exenatide causes greater augmentation in insulin secretion in lean compared with obese individuals but inhibits the brain response to food pictures only in obese individuals.
© 2016 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27489336      PMCID: PMC5864097          DOI: 10.2337/dc15-2706

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  23 in total

1.  Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method.

Authors:  J L Lancaster; L H Rainey; J L Summerlin; C S Freitas; P T Fox; A C Evans; A W Toga; J C Mazziotta
Journal:  Hum Brain Mapp       Date:  1997       Impact factor: 5.038

2.  Bias between MNI and Talairach coordinates analyzed using the ICBM-152 brain template.

Authors:  Jack L Lancaster; Diana Tordesillas-Gutiérrez; Michael Martinez; Felipe Salinas; Alan Evans; Karl Zilles; John C Mazziotta; Peter T Fox
Journal:  Hum Brain Mapp       Date:  2007-11       Impact factor: 5.038

Review 3.  The regulation of food intake by the gut-brain axis: implications for obesity.

Authors:  S S Hussain; S R Bloom
Journal:  Int J Obes (Lond)       Date:  2012-06-19       Impact factor: 5.095

4.  Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans.

Authors:  L van Bloemendaal; D J Veltman; J S Ten Kulve; P F C Groot; H G Ruhé; F Barkhof; J H Sloan; M Diamant; R G Ijzerman
Journal:  Diabetes Obes Metab       Date:  2015-07-22       Impact factor: 6.577

5.  Altered hypothalamic function in response to glucose ingestion in obese humans.

Authors:  M Matsuda; Y Liu; S Mahankali; Y Pu; A Mahankali; J Wang; R A DeFronzo; P T Fox; J H Gao
Journal:  Diabetes       Date:  1999-09       Impact factor: 9.461

Review 6.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Authors:  Daniel J Drucker; Michael A Nauck
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

Review 7.  Type 2 diabetes mellitus.

Authors:  Ralph A DeFronzo; Ele Ferrannini; Leif Groop; Robert R Henry; William H Herman; Jens Juul Holst; Frank B Hu; C Ronald Kahn; Itamar Raz; Gerald I Shulman; Donald C Simonson; Marcia A Testa; Ram Weiss
Journal:  Nat Rev Dis Primers       Date:  2015-07-23       Impact factor: 52.329

8.  Widespread reward-system activation in obese women in response to pictures of high-calorie foods.

Authors:  Luke E Stoeckel; Rosalyn E Weller; Edwin W Cook; Donald B Twieg; Robert C Knowlton; James E Cox
Journal:  Neuroimage       Date:  2008-03-04       Impact factor: 6.556

9.  Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Authors:  P V Højberg; T Vilsbøll; R Rabøl; F K Knop; M Bache; T Krarup; J J Holst; S Madsbad
Journal:  Diabetologia       Date:  2008-11-27       Impact factor: 10.122

10.  Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes.

Authors:  Julio Rosenstock; Sylvia K Shenouda; Richard M Bergenstal; John B Buse; Leonard C Glass; Cory R Heilmann; Anita Y M Kwan; Leigh A MacConell; Byron James Hoogwerf
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112

View more
  8 in total

1.  Exenatide modulates visual cortex responses.

Authors:  Paola Binda; Roy Eldor; Claudia Huerta; John Adams; John Lancaster; Peter Fox; Stefano Del Prato; Ralph DeFronzo; Muhammad Abdul-Ghani; Giuseppe Daniele
Journal:  Diabetes Metab Res Rev       Date:  2019-05-06       Impact factor: 4.876

Review 2.  Renal, metabolic and cardiovascular considerations of SGLT2 inhibition.

Authors:  Ralph A DeFronzo; Luke Norton; Muhammad Abdul-Ghani
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

3.  Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.

Authors:  Muhammad Abdul-Ghani; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2017-08       Impact factor: 19.112

Review 4.  Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.

Authors:  Bruno Geloneze; José Carlos de Lima-Júnior; Lício A Velloso
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

5.  Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.

Authors:  Jae Hyun Bae; Hyung Jin Choi; Kang Ik Kevin Cho; Lee Kyung Kim; Jun Soo Kwon; Young Min Cho
Journal:  Diabetes Metab J       Date:  2019-11-04       Impact factor: 5.376

Review 6.  GLP-1 physiology informs the pharmacotherapy of obesity.

Authors:  Daniel J Drucker
Journal:  Mol Metab       Date:  2021-10-06       Impact factor: 7.422

Review 7.  Regulation of Memory Function by Feeding-Relevant Biological Systems: Following the Breadcrumbs to the Hippocampus.

Authors:  Andrea N Suarez; Emily E Noble; Scott E Kanoski
Journal:  Front Mol Neurosci       Date:  2019-04-18       Impact factor: 5.639

8.  Interaction of circulating GLP-1 and the response of the dorsolateral prefrontal cortex to food-cues predicts body weight development.

Authors:  Lukas Maurer; Knut Mai; Heiko Krude; John-Dylan Haynes; Martin Weygandt; Joachim Spranger
Journal:  Mol Metab       Date:  2019-08-21       Impact factor: 7.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.